Dianthus Therapeutics Statistics
Total Valuation
DNTH has a market cap or net worth of $6.49 billion. The enterprise value is $5.30 billion.
| Market Cap | 6.49B |
| Enterprise Value | 5.30B |
Important Dates
The last earnings date was Tuesday, August 4, 2026, after market close.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DNTH has 55.93 million shares outstanding. The number of shares has increased by 32.34% in one year.
| Current Share Class | 55.93M |
| Shares Outstanding | 55.93M |
| Shares Change (YoY) | +32.34% |
| Shares Change (QoQ) | +16.65% |
| Owned by Insiders (%) | 0.12% |
| Owned by Institutions (%) | 135.77% |
| Float | 55.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3,406.59 |
| Forward PS | 3,724.03 |
| PB Ratio | 5.42 |
| P/TBV Ratio | 5.53 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2,782.03 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 26.10, with a Debt / Equity ratio of 0.00.
| Current Ratio | 26.10 |
| Quick Ratio | 25.79 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -26.07% and return on invested capital (ROIC) is -18.43%.
| Return on Equity (ROE) | -26.07% |
| Return on Assets (ROA) | -17.69% |
| Return on Invested Capital (ROIC) | -18.43% |
| Return on Capital Employed (ROCE) | -18.48% |
| Weighted Average Cost of Capital (WACC) | 4.71% |
| Revenue Per Employee | $20,696 |
| Profits Per Employee | -$2.09M |
| Employee Count | 92 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +456.16% in the last 52 weeks. The beta is 0.08, so DNTH's price volatility has been lower than the market average.
| Beta (5Y) | 0.08 |
| 52-Week Price Change | +456.16% |
| 50-Day Moving Average | 97.22 |
| 200-Day Moving Average | 70.44 |
| Relative Strength Index (RSI) | 62.03 |
| Average Volume (20 Days) | 777,107 |
Short Selling Information
The latest short interest is 8.38 million, so 14.98% of the outstanding shares have been sold short.
| Short Interest | 8.38M |
| Short Previous Month | 9.22M |
| Short % of Shares Out | 14.98% |
| Short % of Float | 15.00% |
| Short Ratio (days to cover) | 8.49 |
Income Statement
In the last 12 months, DNTH had revenue of $1.90 million and -$192.25 million in losses. Loss per share was -$4.11.
| Revenue | 1.90M |
| Gross Profit | 1.90M |
| Operating Income | -217.84M |
| Pretax Income | -192.25M |
| Net Income | -192.25M |
| EBITDA | -217.72M |
| EBIT | -217.84M |
| Loss Per Share | -$4.11 |
Balance Sheet
The company has $886.81 million in cash and $1.29 million in debt, with a net cash position of $1.19 billion or $21.26 per share.
| Cash & Cash Equivalents | 886.81M |
| Total Debt | 1.29M |
| Net Cash | 1.19B |
| Net Cash Per Share | $21.26 |
| Equity (Book Value) | 1.17B |
| Book Value Per Share | 21.39 |
| Working Capital | 863.15M |
Cash Flow
In the last 12 months, operating cash flow was -$155.38 million and capital expenditures -$334,000, giving a free cash flow of -$155.71 million.
| Operating Cash Flow | -155.38M |
| Capital Expenditures | -334,000 |
| Depreciation & Amortization | 123,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -155.71M |
| FCF Per Share | -$2.78 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -11,441.39% |
| Pretax Margin | -10,096.95% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DNTH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -32.34% |
| Shareholder Yield | -32.34% |
| Earnings Yield | -2.96% |
| FCF Yield | -2.40% |
Analyst Forecast
The average price target for DNTH is $137.62, which is 18.68% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $137.62 |
| Price Target Difference | 18.68% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 85.59% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
DNTH has an Altman Z-Score of 35.67 and a Piotroski F-Score of 2.
| Altman Z-Score | 35.67 |
| Piotroski F-Score | 2 |